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A misguided inflammatory response is frequently implicated in myelin damage.
Particularly prominent among myelin diseases, multiple sclerosis (MS) is an autoimmune
condition, with immune–mediated damage central to its etiology. Nevertheless, a
robust inflammatory response is also essential for the efficient regeneration of myelin
sheaths after such injury. Here, we discuss the functions of inflammation that
promote remyelination, and how these have been experimentally disentangled from the
pathological facets of the immune response. We focus on the contributions that resident
microglia and monocyte-derived macrophages make to remyelination and compare the
roles of these two populations of innate immune cells. Finally, the current literature
is framed in the context of developing therapies that manipulate the innate immune
response to promote remyelination in clinical myelin disease.
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REMYELINATION: REGENERATION IN THE CNS
The mammalian central nervous system (CNS) is often considered an archetypal example of a
tissue with poor regenerative potential. This is exemplified by clinical conditions such as spinal
cord injury, stroke, and Alzheimer’s disease, where prognosis is poor due to limited regeneration
of neurons and axons (Tanaka and Ferretti, 2009). Myelin sheaths, however, are an important
exception to this dogma, being a component of the CNS that can regenerate robustly with good
functional outcome; a process termed remyelination (Franklin and Goldman, 2015).
Myelin sheaths are made up of layers of lipid-rich dielectric membrane wrapped around
axons to which they provide electrical insulation and trophic support (Nave and Trapp, 2008).
This membrane is produced by specialized glial cells: oligodendrocytes in the CNS, or Schwann
cells in the peripheral nervous system (PNS). The loss of myelin sheaths with preservation
of the underlying axon is known as demyelination. This is sometimes referred to as primary
demyelination to distinguish it from secondary demyelination, where myelin loss occurs as a
consequence of axonal loss. This latter process is more accurately referred to as Wallerian
degeneration, and we regard the use of the term demyelination in this situation as confusing and
misleading.
Remyelination involves the reinvestment of newmyelin sheaths around intact axons fromwhich
they have been lost (i.e., demyelination; Franklin and Goldman, 2015). This process is performed
by newly generated oligodendrocytes that derive from a pool of oligodendrocyte progenitor cells
(OPCs) following a demyelinating insult. OPCs are present throughout both gray and white
matter in the CNS, and have “stem cell-like” properties such as multipotency and self-renewal
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(Franklin and ffrench-Constant, 2008). In response to
demyelination, OPCs proliferate and migrate to the lesion
site (Di Bello et al., 1999; Crawford et al., 2014) where
they differentiate to mature oligodendrocytes or Schwann
cells, extending processes to remyelinate denuded axons
(Zawadzka et al., 2010). Consequently, saltatory conduction is
restored (Smith et al., 1979) and axons are generally protected
from further degeneration (Irvine and Blakemore, 2008). In
some paradigms, whilst axons are not fully protected, their
degeneration is substantially delayed with motor deficits not
re-appearing until much later timepoints (Manrique-Hoyos
et al., 2012).
Whilst originally characterized in animal models (Bunge et al.,
1961), remyelination is also seen in human patients with MS
(Prineas and Connell, 1979). Amongst MS lesions there is an
associated between remyelination and preservation of axons
(Kornek et al., 2000), although it is in practice difficult to asses
whether remyelination occurs because axons have survived, or
the axons have survived because they are remyelinated. Whilst
extensive in some cases, remyelination efficiency falls as the
disease progresses, so it is usually insufficient to prevent a
patient’s neurological decline as damage gradually accumulates
(Goldschmidt et al., 2009; Franklin et al., 2012).
Crucially, regenerative processes become less efficient with
increasing age, and remyelination is no exception (Shields et al.,
1999). This tenet of regenerative medicine is particularly relevant
in a chronic disease such as MS, which spans several decades
(Franklin, 2002). Aging brings about intrinsic changes in OPCs
(Shen et al., 2008) and their environmental signals (Zhao et al.,
2006), both of which negatively impact remyelination. Because
of this age-related decline, many key findings have come from
comparing remyelination or clinical outcome in young and old
animals (Hinks and Franklin, 2000; Zhao et al., 2006; Shen et al.,
2008) or human cases (Confavreux and Vukusic, 2006). More
interventional approaches have manipulated these systems to
identify pathways crucial for efficient remyelination in young
animals (Kotter et al., 2001; Lampron et al., 2015; Natrajan et al.,
2015) or that can rejuvenate remyelination in older animals
(Ruckh et al., 2012; Miron et al., 2013).
When remyelination fails, the limiting step is most commonly
OPC differentiation, a term encompassing the establishment
of axonal contact, activation of myelin synthesis pathways and
the wrapping and compaction of the newly generated sheath
(Franklin and ffrench-Constant, 2008). In humans, this is
evidenced by an abundance of undifferentiated oligodendrocyte
lineage cells in many chronic MS lesions, which fail to
remyelinate (Wolswijk, 1998; Kuhlmann et al., 2008). Thus,
there is much clinical need for therapies to enhance OPC
differentiation and endogenous remyelination. One avenue for
this is to target the innate immune system.
INNATE IMMUNE CELLS OF THE CNS
The immune system is the network of cellular and molecular
elements that protect an organism from disease. In vertebrates, it
can broadly be divided into the innate and the adaptive immune
systems, though these two branches communicate extensively
and various components, such as innate lymphoid cells, share
features of both. In general, the innate immune system responds
rapidly and relatively non-specifically to infection or damage,
whilst the adaptive immune systemmounts a slower, long-lasting
response to specific targets. Inflammation describes an immune-
mediated response to stimuli that are perceived as harmful, such
as invading pathogens or tissue damage.
Like other tissues, the CNS has its own battalion of
resident tissue macrophages, called microglia. These are innate
immune cells that, in the healthy brain, serve physiological
functions in synaptic plasticity (Paolicelli et al., 2011) and
clearance of debris (Ferrer et al., 1990). Meanwhile, microglia
continuously survey their microenvironment for stimuli that
might indicate injury or infection, and are ready to respond
to this by entering an activated state characterized by cytokine
secretion, phagocytosis and, on occasions, direct cytotoxicity
(Nimmerjahn et al., 2005).
After such a stimulus, microglia may be supplemented
by a second population of macrophages from the periphery.
These differentiate from blood monocytes that have infiltrated
the CNS in response to tissue damage, and thus originate
in the bone marrow. Key differences exist between resident
microglia and these monocyte-derived macrophages, including
their disparate developmental origins (Ginhoux et al., 2010), their
transcriptomic signatures (Hickman et al., 2013) and capacity for
local self-renewal and expansion (Ajami et al., 2007). However,
in a demyelinated lesion, both cell types show high levels of
activation and only recently have successful attempts been made
to phenotypically and functionally distinguish between them, as
will be discussed.
Besides microglia and monocyte-derived macrophages, an
array of other innate immune cells can be found in a
demyelinating lesion. Whilst neutrophils (Liu et al., 2010), mast
cells (Letourneau et al., 2003), and dendritic cells (Karni et al.,
2006) can contribute to demyelination, with a disputed role of
natural killer cells in promoting/limiting damage (Maghazachi,
2012), little evidence exists to support a substantial contribution
of these cell types to remyelination (Mayo et al., 2012). Thus,
in our discussion of CNS remyelination and the innate immune
system, our focus is primarily on microglia and infiltrating
macrophages.
INNATE IMMUNE CELLS AND MYELIN
DISEASE
In MS, aberrant activity of the innate immune system can
contribute to myelin damage. The driver of this is a defective
adaptive immune response involving autoreactive T cells, but
through innate-adaptive cross talk, microglia and monocyte-
derived macrophages can be recruited and mediate a substantial
part of the damage (Compston and Coles, 2002). Based on this
etiology, clinical therapies for MS tend to focus on inhibiting
the adaptive immune system. Examples include the monoclonal
antibodies natalizumab, which impairs T cell trafficking into the
CNS (Polman et al., 2006), and rituximab, which targets CD20 to
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deplete autoantibody-producing B cells (Castillo-Trivino et al.,
2013).
A commonly used range of models for MS is experimental
autoimmune encephalomyelitis (EAE), in which an inoculated
animal develops autoreactive T-cells targeting myelin. This is
a useful paradigm for modeling many of the immunogenic
features of MS (Robinson et al., 2014). However, the complex
inflammatory pathogenesis of these models can mask beneficial
regenerative effects of the innate immune system that may
occur concurrently with negative, disease-contributing innate
cell functions. As such, delineating specific regenerative functions
of innate cells and signals in EAE is challenging. In contrast,
toxin-inducedmodels of demyelination, such as focal lysolecithin
injection, have more discrete phases of demyelination and
remyelination. As the myelin damage is initiated directly
by the toxin, we can generally assume that immune cell
activity during the remyelination phase is a response to myelin
damage, rather than an on-going cause. We will see how
such a response can indeed contribute to the process of
remyelination.
THE CRITICAL ROLE OF THE INNATE
IMMUNE SYSTEM
Making use of these toxin-induced demyelination models, a
beneficial role of the innate immune system in remyelination was
demonstrated in rats depleted of circulating monocytes (Kotter
et al., 2001). This was achieved by systemic treatment with
clodronate liposomes, which are toxic to cells that phagocytose
them. Treated animals had fewer inflammatory cells in the
lesion suggesting a muted innate immune response to tissue
damage and, interestingly, a lower proportion of their axons were
remyelinated post-lesion.
Conversely, by promoting inflammation it is possible to
increase the efficiency of myelin formation. This was shown by
using transplanted OPCs to myelinate retinal ganglion cell axons,
which are normally unmyelinated prior to where they form the
optic nerve (Setzu et al., 2006). Administration of the Toll-Like
Receptor 2 agonist zymosan greatly increased the number of
activated macrophages and the degree of myelination by the
transplanted OPCs. Thus, the link between an inflammatory
response and remyelination has been shown in both “loss-of-
function” and “gain of function” experiments.
A beneficial role of the innate immune system in
remyelination is less clear-cut in models where inflammation also
contributes to the damage. In EAE, similar to MS, both microglia
and infiltrating monocytes are implicated in demyelination
(Fife et al., 2000; Heppner et al., 2005; Ajami et al., 2011).
However, evidence also suggests that subsets of these cells
can play beneficial roles in limiting damage and promoting
remyelination. Macrophages can modulate their phenotypes
in response to extracellular cues (Edwards et al., 2006), often
termed “M1” (pro-inflammatory) or “M2” (anti-inflammatory)
polarization for convenience, though in reality representing
a spectrum with a broad degree of plasticity (Murray et al.,
2014). A shift toward the anti-inflammatory M2 phenotype is
associated with a milder clinical picture in EAE (Mikita et al.,
2011), and administration of M2-polarized monocytes to EAE
animals can enhance differentiation of oligodendrocytes and
improve symptoms (Butovsky et al., 2006). This is consistent
with a crucial shift from pro- to anti-inflammatory phenotypes
in remyelination of toxin-induced lesions (Miron et al., 2013).
Myeloid-derived suppressor cells are a subpopulation of innate
immune cells that typically expressM2markers and limit damage
in EAE at peaks of disability, in part by promoting apoptosis of
T lymphocytes (Moliné-Velázquez et al., 2011).
Thus, even on a backdrop of inflammatory damage, cells of
the innate immune system can play beneficial roles in outcome
and may contribute to remyelination. This is important for
the application of findings from toxin-induced models to the
immune-mediated pathology of MS. Indeed, post-mortem data
from MS patients, shows a correlation between the density of
macrophages and the density of OPCs within a lesion (Wolswijk,
2002). MS lesions can be classified by their histopathology: active
plaques, which have on-going inflammation, show the highest
levels of OPC recruitment and remyelination, whilst chronic
active and chronic inactive plaques show little inflammation
and remyelination is rare (Clemente et al., 2013). Lesions that
remyelinate successfully become shadow plaques, in which axons
are relatively preserved. Reactivation of inflammation in chronic
plaques may be a strategy to overcome their remyelination failure
(Franklin and Goldman, 2015).
The decline of remyelination efficiency with age also occurs
in part at the level of the innate immune system. This was
demonstrated using a heterochronic parabiosis system, in which
mice of different ages are connected via their circulatory systems
(Ruckh et al., 2012). Remyelination of a toxin-induced lesion
is rejuvenated in old mice that are exposed to the systemic
environment of a younger mouse. The effect was abrogated in
mice that lacked CCR2, a receptor necessary for monocyte entry
into the CNS, suggesting that young macrophages are able to
stimulate old OPCs to differentiate more efficiently. A timely shift
from pro- to anti-inflammatory innate immune cell phenotypes
is important for efficient remyelination (Miron et al., 2013), a
phenomenon also seen in regeneration of other tissues, including
skin (Deonarine et al., 2007). This shift is diminished with
aging, but rejuvenated by heterochronic parabiosis (Miron et al.,
2013), and appears to be instrumental in the rejuvenation of
remyelination.
The positive relationship between remyelination and
inflammation is strikingly similar to results seen across a
broad range of regeneration paradigms. Healing of other
murine tissues such as skin (Mirza et al., 2009) is impaired
when macrophages are subject to selective genetic ablation.
The famously extensive regrowth of salamander limbs after
amputation is also diminished when macrophages are depleted
by a toxic liposome treatment (Godwin et al., 2013). Even
in the planarian flatworm, a remarkable organism capable
of regenerating any of its tissues after transection, primitive
macrophage-like cells are abundant at the site of injury (Peiris
et al., 2014). The conservation of this phenomenon across
the animal kingdom gives further weight to the idea that
remyelination requires a robust inflammatory response.
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HOW DO INNATE IMMUNE CELLS
CONTRIBUTE TO REMYELINATION?
The most important functions of innate immune cells in
remyelination appear to be (1) phagocytosis of debris and
(2) secretion of growth signals, cytokines and other factors.
Through, a combination of these mechanisms, microglia,
and monocyte-derived macrophages can fashion a pro-
regenerative environment that maximizes the potential of
OPCs to differentiate and replace the myelin on denuded axons
(Figure 1).
Macrophages are well known for their phagocytosis of
invading pathogens, cellular debris and apoptotic host cells.
In a lesion where myelin sheaths are destroyed, much of this
phagocytic response is directed toward fragments of myelin,
which can linger in the environment. CNS myelin inhibits
OPC differentiation in vitro (Robinson and Miller, 1999) and
in vivo it was shown that remyelination is impaired if a
lesion is supplemented with additional myelin debris (Kotter
et al., 2006). This would suggest that clearance of myelin
debris by phagocytosis is necessary for OPCs to produce
new oligodendrocytes. More direct evidence for this comes
from recent studies showing reduced remyelination when
phagocytosis is specifically impaired in microglia (CX3CR1
knockout, Lampron et al., 2015) or in infiltrating macrophages
(LysM-specific RXRα knockout, Natrajan et al., 2015).
Inflammation can also contribute to remyelination through
phagocytosis-independent mechanisms. This is apparent
during the enhanced myelination of retinal ganglion cells by
transplanted OPCs when inflammation is stimulated (Setzu
et al., 2006). These axons are not myelinated under normal
conditions, so there is accordingly no myelin debris for innate
immune cells to clear. Innate immune cells can secrete a wide
array of factors that contribute to the lesion environment,
and these are disturbed in older animals, which have a lower
capacity for remyelination (Hinks and Franklin, 2000; Zhao
et al., 2006). The ability of microglia-conditioned media to
modulate OPC behavior in vitro is further evidence of secreted
factors promoting remyelination. Media conditioned by pro-
inflammatory M1 microglia, which appear soon after a lesion,
promote OPC proliferation, whilst media conditioned by M2
anti-inflammatory microglia, which peak later, prevent apoptosis
and encourage differentiation to oligodendrocytes (Miron et al.,
2013).
Several specific factors are known to be produced during
inflammation and promote remyelination. Insulin-like growth
factor (IGF-1) and transforming growth factor-β (TGF-β) have
long been known to promote OPC differentiation in vitro
(McMorris and Dubois-Dalcq, 1988; McKinnon et al., 1993)
and their expression is delayed in the slow remyelination of
old rats (Hinks and Franklin, 2000). More recently, endothelin
2 was identified by transcriptional profiling of the OPC retinal
transplant model (Yuen et al., 2013) and activin-A was found to
be essential for the microglia-conditioned media effects on OPC
differentiation (Miron et al., 2013). The msh-like homeobox-3
gene (Msx3) appears to be an important positive regulator for
the M2 phenotype and for expression of activin-A and IGF-1.
Overexpression of Msx3 in transplanted microglia enhances
remyelination in both EAE and lysolecithin models (Yu et al.,
2015).
DIVERGENT ROLES FOR MACROPHAGES
AND MICROGLIA
The two key functions of phagocytosis and mediator secretion
can be carried out by both resident microglia and infiltrating
macrophages, which are often discussed as a single functional
population. However, as our models of remyelination and the
tools to probe them becomemore sophisticated, more differences
between these two pools of innate immune cells are emerging.
A comparison of the transcriptomes of microglia and
peripherally-derived macrophages revealed several hundred
genes that could distinguish between the two populations,
largely related to sensing endogenous ligands and microbes
(Hickman et al., 2013). This may become less pronounced
when microglia become activated in a lesion environment,
as inflammatory stimuli can substantially alter the microglial
transcriptome (Bodea et al., 2014). Nevertheless, it is possible
to determine the origin of innate immune cells in EAE
lesions based on maintained molecular signatures: notably, the
microglial-specific surface markers P2ry12, FCRLS (Butovsky
et al., 2014), and Tmem119 (Bennett et al., 2016) are maintained
during inflammation, and are not upregulated in monocyte-
derived macrophages. Prior to these recent advances, the use
of blood-brain barrier impermeable toxins have been used
to specifically ablate peripherally-derived macrophages, whilst
fluorescent bone-marrow chimeras have allowed peripheral cells
to be tracked upon entry to the CNS.
These techniques have demonstrated how microglia and
infiltrating macrophages have a high degree of overlap in
their function. Microglia appear to undergo a compensatory
proliferation in lesions lacking monocyte-derived macrophages
due to peripheral ablation (Kotter et al., 2005). Using a green
fluorescent protein-positive (GFP+) bone marrow chimera, it
was shown that the transition fromM1 to M2 phenotypes occurs
similarly in both microglia and infiltrating macrophages after a
lysolecithin-induced lesion (Miron et al., 2013). The infiltration
of young monocytes into an old lesion in the heterochronic
parabiosis model accelerates the shift from M1 dominance to
M2 dominance within the lesion and likely contributes to the
enhanced remyelination. Relatively few cells in the lesion were
derived from a GFP+ young partner, suggesting that these
infiltrating cells were influencing endogenous innate immune
cells to create a pro-regenerative environment.
Other experiments have elucidated divergent functions of
microglia and monocyte-derived macrophages in remyelination.
When demyelination was induced by dietary cuprizone, blocking
peripheral monocyte infiltration by CCR2 deficiency was
inconsequential to the regenerative process (Lampron et al.,
2015), in contrast to the importance of this process for efficient
remyelinating of a sterotactic lysolecithin lesion (Ruckh et al.,
2012). Endogenous microglia, on the other hand, were shown to
be vital as remyelination was impaired in a CX3CR1 microglial
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FIGURE 1 | The actions of innate immune cells during remyelination. Innate immune cells in a demyelinated lesion can derive from activation of CX3CR1+
resident ramified microglia (green). Alternatively they may originate from blood monocytes (pink), which are recruited from the circulation in a CCR2-dependent manner
and differentiate into macrophages. CX3CR1 and CCR2 have proved useful for genetically labeling or ablating the separate populations. Once activated, these cells
become difficult to distinguish based on morphology and classical immunohistochemical techniques (striped), though some surface markers have recently been
observed specifically in microglia, including Tmem119, P2ry12, and FCRLS. Innate immune cells can phagocytose inhibitory myelin debris and secrete an array of
pro-regenerative factors, some of which are positively regulated by the transcription factor Msx3. The combination of these functions promotes the differentiation of
OPCs (purple) and subsequent reinvestment of new myelin sheaths around denuded axons (blue).
receptor knockout mouse model. In the dietary cuprizone
model, demyelination occurs without the blood-brain barrier
damage of stereotactic injection (Bakker and Ludwin, 1987),
which may account for the reduced role of monocyte-derived
macrophages, though these cells were still able to infiltrate
the lesioned CNS (Lampron et al., 2015). Additionally this
study did not look at aging, which may be a context in which
CCR2-dependent monocyte recruitment becomes more critical.
Divergent roles for endogenous and infiltrating components
were also observed when EAE was induced in transgenic mice
with green CX3CR2+ microglia and red CCR2+ macrophages
(Yamasaki et al., 2014). In this case, highly activated monocyte-
derived macrophages appear to initiate demyelination,
whilst microglia had more beneficial roles in clearing
debris.
This rapidly expanding body of evidence is leading us away
from a model of a single macrophage/microglia compartment
in a demyelinated lesion. Significant transcriptional differences
in sensome genes (Hickman et al., 2013) suggest that the two
populations can respond differently to the same environmental
stimuli. The manifestation of these differences seems to depend
strongly on the experimental model, perhaps implying that
differences in age or blood-brain barrier function are important
(Ruckh et al., 2012; Lampron et al., 2015). In EAE, where the
pathology is immune-mediated, infiltrating macrophages and
resident microglia may even have opposing roles, promoting de-
and re-myelination respectively (Yamasaki et al., 2014). However,
this result contrasts with a beneficial effect of specifically blocking
resident microglial activation, even in EAE with the same
immunogen (Heppner et al., 2005). In any case, the high
variability between experimental setups suggests that the relative
contributions of these two innate immune cell populations will
likely differ between individual clinical myelin disorders, their
stages and lesion types.
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INFLAMMATORY THERAPIES FOR
REGENERATION IN MYELIN DISEASE?
A range of clinical diseases involve primary demyelination,
the causes of which can be intrinsic or extrinsic to the
oligodendrocyte lineage. Intrinsic causes account for
the leukodystrophies, in which genetic mutations affect
production of myelin proteins and other oligodendrocyte
functions. Alternatively, the pathology can originate from the
oligodendrocytes’ environment, for example inflammation in
MS, or toxicity as in many model systems. Whilst cell therapy is
a promising avenue for leukodystrophies, diseases that originate
externally will most likely benefit from interventions that lessen
the demyelinating insult and promote endogenous remyelination
(Franklin and Goldman, 2015).
Currently, most disease-modifying drugs used to treat MS
focus on modulating the adaptive immune response using small
molecules or monoclonal antibodies. These can be effective
in reducing the length and frequency of relapses and provide
symptomatic relief, though there is limited impact on the
progressive phase of the disease and no curative agents are
currently in clinical use (Goldenberg, 2012). Modulating the
innate immune response to promote endogenous remyelination
is a potential means to salvage denuded axons and prevent
progression of the disease.
Microglia and infiltrating macrophages promote
remyelination through important roles in debris clearance
and secretion of factors into their local environment. These
two functions become gradually less efficient as an animal ages
(Hinks and Franklin, 2000; Ruckh et al., 2012; Natrajan et al.,
2015), though aspects of the decline appear to be reversible
by altering the tissue environment (Linehan et al., 2014).
Compelling evidence from parabiosis shows that remyelination
by previously inefficient OPCs in an old animal can indeed be
rejuvenated by manipulating components of the innate immune
system (Ruckh et al., 2012). Systemic pharmacological activation
of the innate immune system has also been shown to promote
remyelination (Döring et al., 2015). Additionally, as we learn
more about the differences between microglia and monocyte-
derived macrophages, divergent roles may be specifically
targeted to enhance the production of a pro-regenerative
environment.
However, the immune system is a complex network with
much cross-talk between its adaptive and innate branches.
Translational challenges will come in being able to stimulate
the beneficial functions of innate immune cells without
simultaneously fuelling further autoimmune destruction of
myelin sheaths. Additionally, many of the symptoms of MS result
from the death of axons that have already been too long without
the trophic support and protection of myelin (Franklin and
Gallo, 2014). Endogenous remyelination could not reverse the
symptoms associated with previous axonal death, though it could
salvage vulnerable axons at the point between demyelination
and death. As such, remyelinating therapies would address
an important unmet need in the treatment of demyelinating
disease. Such regenerative therapies will likely be additive and
complementary to the current disease-modifying treatments that
can reduce the occurrence of demyelination with variable risks of
adverse effects.
Despite foreseeable challenges, harnessing the pro-
regenerative properties of inflammation has shown extensive
benefit in animal models of remyelination. This approach has
the potential to partially reverse the course of MS when it begins
to makes the transition from bench to bedside.
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